Male enhancement nutraceuticals evaluation in Egypt

Clinical efficacy and safety of products marketed in Egypt under the claim of being natural nutraceuticals for male enhancement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201505001128346

Enrollment

Registered

2015-05-01

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Interventions

Viagra® 50 mg tablets (Sildenafil citrate, Pfizer, USA)

Levitra® 20 mg tablets (Vardenafil HCL, Bayer, Germany)

Cialis® 20 mg tablets (Tadalafil HCL, Eli Lilly, USA)

Starch tablets locally compressed (Erweka Benchtop tablet machine EK 0 / AR 400, Hamburg, Germany)

Tiger King

Hercules

Herbal Viagra

Natural viagra

Plant Viagra

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy married volunteers

Exclusion criteria

Exclusion criteria: Hypertension Diabetes Cardiovascular disease Liver diseases Kidney diseases

Design outcomes

Primary

Measure	Time frame
Concentration of drug in blood;Liver and Kidney functions ;Blood pressure ;Questionnaire; safety and efficacy assessment	—

Countries

Egypt

Contacts

Public ContactAhmed Othman

Study Coordinator

Ahmed.Othman@gmail.com0100 4344084

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026